NEW YORK (GenomeWeb News) – BG Medicine announced today a public offering of units comprising its common stock and warrants that is expected to bring in net proceeds of $2.1 million.

The Waltham, Massachusetts-based firm is offering 2,315,654 Series A units each consisting of one share of common stock and one half of a warrant to purchase one share of common stock at $1 per Series A unit.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.